Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OMO 2

Next Previous
Drug Profile

OMO 2

Alternative Names: DO-2; OMO-2

Latest Information Update: 18 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Pharmaceutica
  • Developer DeuterOncology
  • Class Antineoplastics
  • Mechanism of Action Proto-oncogene protein c-met inhibitors; Ras signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 23 Oct 2024 Pharmacokinetics, adverse events and efficacy data from a phase-I trial in Solid tumours presented at the 36th European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
  • 30 Nov 2023 DeuterOncology plans a phase II trial for solid tumours (DeuterOncology pipeline, November 2023)
  • 20 Dec 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, First-line therapy) in Netherlands, Belgium (PO) (NCT05752552) (EudraCT 2022-001681-35)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top